Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic commentary with no original human data or systematic review methodology.
PubMed 41914150 · doi:10.1093/eurheartj/ehag201
What was done
This narrative review summarizes existing evidence on skeletal muscle and lean mass reduction occurring alongside fat loss during anti-obesity treatment with glucagon-like peptide-1 receptor agonists. The authors discuss mechanistic drivers of muscle catabolism (caloric restriction, anabolic resistance, hormonal alterations) and evaluate strategies to mitigate muscle loss, including resistance training, dietary protein optimization, nutraceuticals, and novel pharmacotherapies (such as myostatin/activin inhibitors and selective androgen receptor modulators).
What was found
The abstract reports no numerical data or effect sizes. It describes a consistent reduction in lean body mass during pharmacologic weight loss and identifies potential risks of sarcopenia, frailty, and diminished cardiovascular resilience, emphasizing the need to focus on high-quality weight loss rather than total weight loss alone.
Why it matters
As potent incretin-based weight loss therapies become standard, preserving skeletal muscle quality and functional capacity is essential to prevent frailty and ensure long-term cardiovascular risk reduction.
Limits
The abstract describes a narrative review without original clinical trial data or systematic synthesis methodology. No quantitative rates of muscle loss, clinical event endpoints, or comparative outcomes for adjunctive interventions are reported.
Cited by
- supports During weight loss diets without resistance training and adequate protein, up to 40% of the total weight lost can come from lean mass.